Peter B. Silverman - 27 Jul 2026 Form 3 Insider Report for Yarrow Bioscience, Inc. (VYNE)

Reporting relationship: Director
Issuer ticker: VYNE
Reported as of: 27 Jul 2026
Net transaction value: $0
SEC form: 3
Accepted by SEC: 29 Jul 2026, 21:17:12 UTC
Prior SEC filing: 24 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Tyler Zeronda, as attorney-in-fact for Peter B. Silverman

Key filing fact

Peter B. Silverman filed Form 3 for Yarrow Bioscience, Inc. (VYNE) on 29 Jul 2026.

Key facts

This page summarizes Peter B. Silverman's Form 3 filing for Yarrow Bioscience, Inc. (VYNE).
0 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 29 Jul 2026, 21:17.

Change

Previous filing in this sequence was filed on 24 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0001790314 Primary reporting owner

Silverman Peter B.

Relationship: Director
Address: C/O YARROW BIOSCIENCE, INC., 470 JAMES STREET, SUITE 007, NEW HAVEN
Signature: /s/ Tyler Zeronda, as attorney-in-fact for Peter B. Silverman
Signature date: 29 Jul 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

VYNE holding Derivative

Stock Option (Right to Buy)

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date: 27 Jul 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 87,820
Exercise price: $6.19
Footnotes: F1, F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Effective as of July 27, 2026 (the "Effective Time"), a wholly owned subsidiary of VYNE Therapeutics Inc. ("VYNE") merged with and into Yarrow Bioscience, Inc. ("Yarrow") with Yarrow continuing as a wholly owned subsidiary of VYNE and the surviving corporation of the merger (the "Merger") under the name "Yarrow Bioscience Operating Company Corp." In connection with the completion of the Merger, VYNE changed its name to "Yarrow Bioscience, Inc." (hereinafter, the "Issuer").

Footnote F2

Represents options to purchase shares of common stock, par value $0.0001, of the Issuer ("Issuer Common Stock") received by the Reporting Person in the Merger in exchange for options to purchase shares of common stock of Yarrow held by the Reporting Person prior to the Merger. At the Effective Time, the Issuer assumed each such Yarrow option, whether vested or unvested, and converted it into an option to purchase shares of Issuer Common Stock on the same terms and conditions as were in effect immediately prior to the Effective Time.

Footnote F3

This option represents a right to purchase 87,820 shares of Issuer Common Stock, one quarter of which will vest on April 17, 2027, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

SEC remarks

Exhibit 24 - Power of Attorney